Lynne Powell Sells 2,000 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) VP Lynne Powell sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, January 18th. The stock was sold at an average price of $9.40, for a total transaction of $18,800.00. Following the sale, the vice president now owns 2,000 shares of the company’s stock, valued at approximately $18,800. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Lynne Powell also recently made the following trade(s):

  • On Wednesday, January 16th, Lynne Powell sold 3,046 shares of BioCryst Pharmaceuticals stock. The shares were sold at an average price of $9.27, for a total transaction of $28,236.42.
  • On Monday, January 14th, Lynne Powell sold 954 shares of BioCryst Pharmaceuticals stock. The shares were sold at an average price of $9.20, for a total transaction of $8,776.80.
  • On Monday, December 10th, Lynne Powell sold 4,000 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $9.06, for a total transaction of $36,240.00.
  • On Tuesday, November 20th, Lynne Powell sold 15,470 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $8.55, for a total transaction of $132,268.50.
  • On Thursday, November 8th, Lynne Powell sold 5,280 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $8.15, for a total transaction of $43,032.00.
  • On Monday, November 5th, Lynne Powell sold 100 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $800.00.
  • On Thursday, November 1st, Lynne Powell sold 1,544 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $7.51, for a total transaction of $11,595.44.

Shares of BioCryst Pharmaceuticals stock traded down $0.12 during trading on Wednesday, hitting $8.81. 25,638 shares of the stock traded hands, compared to its average volume of 591,986. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -11.28 and a beta of 1.70. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.00 and a quick ratio of 1.98. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.25 and a twelve month high of $9.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. The company had revenue of $1.45 million during the quarter, compared to analyst estimates of $2.53 million. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.99 earnings per share for the current year.

Several brokerages have recently weighed in on BCRX. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.75 price target on the stock in a report on Tuesday, October 9th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 12th. Piper Jaffray Companies started coverage on shares of BioCryst Pharmaceuticals in a research report on Friday, November 16th. They issued an “overweight” rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada raised their price target on shares of BioCryst Pharmaceuticals to $16.00 and gave the stock a “positive” rating in a research report on Tuesday, December 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.18.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Vanguard Group Inc grew its stake in shares of BioCryst Pharmaceuticals by 9.2% during the third quarter. Vanguard Group Inc now owns 5,798,229 shares of the biotechnology company’s stock valued at $44,240,000 after buying an additional 490,319 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 9.2% in the third quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after purchasing an additional 490,319 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 4.1% in the third quarter. Teachers Advisors LLC now owns 294,786 shares of the biotechnology company’s stock worth $2,249,000 after purchasing an additional 11,682 shares during the last quarter. MetLife Investment Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 84.7% in the third quarter. MetLife Investment Advisors LLC now owns 79,206 shares of the biotechnology company’s stock worth $604,000 after purchasing an additional 36,325 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its stake in shares of BioCryst Pharmaceuticals by 7.8% in the third quarter. Baker BROS. Advisors LP now owns 15,103,081 shares of the biotechnology company’s stock worth $115,237,000 after purchasing an additional 1,090,909 shares during the last quarter. Institutional investors and hedge funds own 91.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2019/01/23/lynne-powell-sells-2000-shares-of-biocryst-pharmaceuticals-inc-bcrx-stock.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Further Reading: Understanding Market Liquidity

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply